Top 10 Companies in the (S)-5-Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (S)-5-Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide market size was valued at USD 18.4 million in 2025. The market is expected to grow from USD 19.6 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide is a specialized chiral pharmaceutical intermediate and fine chemical compound characterized by its thiophene ring structure with a chloro substituent and an oxiranylmethyl‑amide functional group. It serves as a key building block in the synthesis of active pharmaceutical ingredients (APIs), particularly in the development of anticoagulant and cardiovascular therapeutic agents, most notably as an intermediate in the manufacture of rivaroxaban.

The market is steadily gaining traction, driven by the expanding global demand for rivaroxaban‑based anticoagulant therapies and the broader growth of the pharmaceutical fine chemicals sector. Further, increasing investments in asymmetric synthesis technologies and rising outsourcing of API manufacturing to contract development and manufacturing organizations (CDMOs) are reinforcing market expansion. Key suppliers and chemical manufacturers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Fluorochem, among other specialized fine chemical producers with established chiral synthesis capabilities.

(S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide Market – View in Detailed Research Report

🔟 1. Asymchem Laboratories

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates for anticoagulant APIs

Asymchem Laboratories has positioned itself as a leading supplier of chiral intermediates for the global pharmaceutical industry. The company’s advanced asymmetric synthesis platform delivers consistent enantiomeric excess, ensuring that its (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide meets the stringent quality expectations of major API developers.

Sustainability & Growth Initiatives:

• Investments in continuous‑flow asymmetric catalysis to reduce solvent use.
• Development of bio‑based chiral auxiliaries to lower carbon footprint.
• Strategic partnership with a leading global CDMO to expand market reach.

9️⃣ 2. Hikal Ltd.

Headquarters: Bengaluru, India
Key Offering: Custom synthesis of chiral intermediates for cardiovascular drugs

Hikal’s state‑of‑the‑art chiral synthesis infrastructure allows the company to provide (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide at scale while maintaining high enantiomeric purity. Its strong presence in the Indian generic API market gives it a competitive advantage in securing long‑term supply contracts.

Sustainability & Growth Initiatives:

• Implementation of green chemistry protocols to cut hazardous reagent use.
• Adoption of renewable energy sources in production facilities.
• Collaboration with academic partners to explore novel chiral catalysts.

8️⃣ 3. Divi’s Laboratories

Headquarters: Pune, India
Key Offering: High‑purity chiral intermediates for anticoagulant and anti‑diabetic APIs

Divi’s Laboratories leverages its robust GMP‑compliant manufacturing network to deliver (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide to a global portfolio of pharmaceutical clients. The company’s focus on process scalability ensures reliable supply for both originator and generic manufacturers.

Sustainability & Growth Initiatives:

• Optimization of reaction conditions to lower energy consumption.
• Development of recyclable chiral catalysts.
• Expansion of contract manufacturing services to emerging markets.

7️⃣ 4. Zhejiang Hisun Pharmaceuticals

Headquarters: Hangzhou, China
Key Offering: Integrated chiral synthesis and purification solutions

Zhejiang Hisun combines upstream chiral synthesis with downstream purification to provide a single‑source solution for (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide. The company’s focus on process integration reduces batch turnaround time, a critical factor for time‑sensitive API production.

Sustainability & Growth Initiatives:

• Implementation of solvent‑free reaction protocols.
• Partnership with a leading CDMO to expand global distribution.
• Continuous improvement of chiral resolution processes to enhance yield.

6️⃣ 5. Aurobindo Pharma

Headquarters: Hyderabad, India
Key Offering: Custom synthesis of chiral intermediates for generic API production

Aurobindo Pharma’s in‑house synthesis capabilities allow the company to secure supply of (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide for its extensive generic portfolio. The firm’s focus on process optimization ensures consistent enantiomeric purity across production batches.

Sustainability & Growth Initiatives:

• Adoption of greener reaction media to reduce hazardous waste.
• Investment in automated synthesis platforms to improve reproducibility.
• Collaboration with regional universities to develop next‑generation chiral catalysts.

5️⃣ 6. Laurus Labs

Headquarters: Bangalore, India
Key Offering: High‑purity chiral intermediates for cardiovascular and anti‑inflammatory APIs

Laurus Labs has built a reputation for delivering chiral intermediates with stringent quality specifications. Its focus on continuous process development supports scalable production of (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling systems.
• Exploration of bio‑based starting materials.
• Expansion of contract manufacturing services to tier‑2 markets.

4️⃣ 7. Lonza Group

Headquarters: Basel, Switzerland
Key Offering: Custom synthesis and scale‑up of chiral intermediates for API development

Lonza’s global footprint and expertise in chiral synthesis enable the company to provide (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide to a broad portfolio of pharmaceutical developers. The firm’s focus on analytical rigor ensures that its intermediates meet the most demanding quality criteria.

Sustainability & Growth Initiatives:

• Investment in enzymatic resolution to reduce toxic reagents.
• Partnerships with academic institutions for catalyst development.
• Expansion of its contract manufacturing network across emerging markets.

3️⃣ 8. Cambrex Corporation

Headquarters: Northbrook, USA
Key Offering: Custom synthesis of chiral intermediates for API and specialty chemical markets

Cambrex’s advanced synthesis capabilities and flexible batch sizes make it a preferred partner for early‑stage drug discovery programs requiring (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide. The company’s focus on rapid scale‑up supports time‑sensitive API development.

Sustainability & Growth Initiatives:

• Adoption of continuous flow chemistry to lower waste.
• Development of chiral organocatalysts to reduce reliance on heavy‑metal catalysts.
• Strategic alliance with a leading CDMO to broaden distribution channels.

2️⃣ 9. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: High‑purity chiral intermediates for pharmaceutical development

Sigma‑Aldrich’s extensive catalog and global supply network make it a trusted source for (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide. The company’s focus on analytical validation ensures that each batch meets the most rigorous quality standards.

Sustainability & Growth Initiatives:

• Implementation of solvent‑reduction strategies across production lines.
• Investment in renewable energy for manufacturing sites.
• Collaboration with academic partners to advance asymmetric catalysis.

1️⃣ 10. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Custom synthesis and supply of chiral intermediates for pharmaceutical and specialty chemical sectors

TCI Chemicals leverages its strong presence in the Asian market to deliver (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide to a diverse portfolio of clients. The company’s focus on process innovation supports rapid scale‑up for both originator and generic manufacturers.

Sustainability & Growth Initiatives:

• Adoption of green solvent systems in synthesis routes.
• Implementation of energy‑efficient reactors.
• Partnership with a leading CDMO to extend market reach.

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307870/chlorothiophenecarboxylic-acid-oxiranylmethylamide-market

Get Full Report: https://www.24chemicalresearch.com/reports/307870/chlorothiophenecarboxylic-acid-oxiranylmethylamide-market

Outlook

The market is expected to move from USD 19.6 million in 2026 to USD 34.2 million by 2034, reflecting a CAGR of 7.2% over the forecast period. The sustained demand for rivaroxaban and the expansion of generic API production are the main drivers of this trajectory. The increasing focus on chiral purity and regulatory compliance will keep the supply chain tightly aligned with quality expectations.

Future Trends

1. Advances in chiral synthesis technologies – Enzymatic resolution and asymmetric organocatalysis are gaining traction, offering higher enantiomeric excess with lower environmental impact.

2. Growing CDMO outsourcing – Pharmaceutical developers are increasingly partnering with CDMOs to secure reliable supply of (S)-5‑Chloro‑thiophene‑2‑carboxylic acid oxiranylmethyl‑amide, reducing in‑house synthesis burden.

3. Green chemistry adoption – Continuous flow processes and solvent‑free reactions are being integrated to lower waste and improve cost efficiency.